cbdMD Past Earnings Performance

Past criteria checks 0/6

cbdMD's earnings have been declining at an average annual rate of -13.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 11.2% per year.

Key information

-13.6%

Earnings growth rate

12.1%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-11.2%
Return on equity-188.5%
Net Margin-39.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry?

Mar 23
cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry?

This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD)

Feb 23
This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD)

If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today

Feb 09
If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today

We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide

Jan 13
We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide

Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly?

Dec 15
Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly?

Revenue & Expenses Breakdown

How cbdMD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSEAM:YCBD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2419-8130
30 Jun 2421-23130
31 Mar 2422-26150
31 Dec 2323-24160
30 Sep 2324-27190
30 Jun 2326-26210
31 Mar 2329-56230
31 Dec 2232-59280
30 Sep 2235-74331
30 Jun 2237-63381
31 Mar 2239-29441
31 Dec 2141-37451
30 Sep 2144-26431
30 Jun 2146-28411
31 Mar 2146-38361
31 Dec 2044-10371
30 Sep 204212390
30 Jun 204031410
31 Mar 203715450
31 Dec 1933-32390
30 Sep 1924-45290
30 Jun 198-60150
31 Mar 193-3560
31 Dec 180-220
30 Sep 180-220

Quality Earnings: YCBD is currently unprofitable.

Growing Profit Margin: YCBD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: YCBD is unprofitable, and losses have increased over the past 5 years at a rate of 13.6% per year.

Accelerating Growth: Unable to compare YCBD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YCBD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: YCBD has a negative Return on Equity (-188.45%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 20:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

cbdMD, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael HickeyBenchmark Company
William SutherlandBenchmark Company
Pablo ZuanicCantor Fitzgerald & Co.